期刊文献+

西格列汀中间体新合成方法

New synthetic method of the intermediate of sitagliptin
原文传递
导出
摘要 L-门冬氨酸在氯化亚砜作用下选择性甲酯化生成L-门冬氨酸-4-甲酯盐酸盐,经二碳酸二叔丁酯保护氨基,再与N-甲基吗啉,氯甲酸叔丁酯低温下反应,加入硼氢化钠还原,得(3S)-3-(叔丁氧羰基氨基)-4-羟基丁酸甲酯,与对甲基苯磺酰氯反应后的产物继续与格式试剂(2,4,5-三氟苯基)溴化镁、溴化亚铜二甲硫醚反应,经氢氧化钠水解,调酸得化合物Boc-(R)-3-氨基-4-(2,4,5-三氟苯基)丁酸。 L-aspartic acid-4-methyl ester hydrochloride was obtained using L-aspartic acid as material by the action of thionyl chloride with selectively esterification.(3S)-3-(tert-butoxycarbonyl-amino)-4-hydroxyl methyl butyrate was got with follow reaction:the protecting amino using tert-butyl dicarbonate,then reacting with methyl N-morpholine,tert-butyl chloroformate under low temperature,reducing reaction using sodium borohydride.The compound Boc-(R)-3-amino-4-(2,4,5-trifluorophenyl)butyric acid was obtained with follow reaction:by reaction using(3S)-3-(tert-butoxycarbonyl-amino)-4-hydroxyl methyl butyrate with p-toluenesulfonyl chloride,than continuting reaction with a Grignard reagent,at last by hydrolysis of lithium hydroxide.
出处 《精细与专用化学品》 CAS 2016年第5期40-43,共4页 Fine and Specialty Chemicals
关键词 西格列汀 中间体 格式试剂 Ⅱ型糖尿病 sitagliptin intermediate format reagents typeⅡ diabetes
  • 相关文献

参考文献12

  • 1张媛媛,马向华,沈捷.二肽基肽酶Ⅳ抑制剂西他列汀的研究进展[J].江苏医药,2011,37(21):2565-2567. 被引量:3
  • 2孙桂芳,蔡正艳,周伟澄.西他列汀合成路线图解[J].中国医药工业杂志,2008,39(5):383-386. 被引量:12
  • 3郭锦材,张拥军,张兴贤.(3S)-3-(叔丁氧羰基氨基)-4-氧代丁酸甲酯的合成[J].中国医药工业杂志,2012,43(3):172-174. 被引量:1
  • 4Katritzky A R, Tao H, Jiang R, et al. Novel Syntheses of ehiral/?-and 7-amino acid derivatives utilizing N-proteeted(amin-oaeyl)henzowiazoles from aspartie and ghtamie aeids[J]. J Org Chem, 2007, 72(2)407-414.
  • 5Ramalingam K, Woodard R W. Synthesis of stereospecific deu- terium-labeled homoserines and homoscdne lactonesI-J. J Org Chem, 1988, 53(9) :1900-1903.
  • 6Markidis T, Kokotos G. A novel approach to the synthesis of chiral terminal 1,2-diamines[J]. J 0rg Chem, 2001, 66 (5) : 1919-1923.
  • 7邢其毅,裴伟伟,徐瑞秋,等.基础有机化学(第三版)[M].北京:高等教育出版社,2006.297.
  • 8Anelli P L, Biffi C, Montanafi F, et al. Fast and selective oxi- dation of primary alcohols to aldehydes or to carboxylic acids and of secondary alcohols to ketones mediated by oxoammonium salts under two-phase conditions[J], J org Chem, 1987, 52 (12) .. 2559-2562.
  • 9朱国良,张健,杨立军,等.西他列汀中间体及其制备方法和用途[P].WO20110305725,2011-03-31.
  • 10Robert A B, Dudley C S. Mechanism of the reaction between henzy[magnesium chloride and earbonyl compounds. A detailed study with formaldehyde[J]. American Chemical Society, 1982, 47(7) :1243-1249.

二级参考文献46

  • 1Orskov C, Wettergren A, Hoist JJ. Biological effects and metabolic rales of glucagonlike peptide-17-36 amide and glucagonlike peptide-17-37 in healthy subjects are indistin- guishable[J]. Diabetes, 1993,42 (5) : 658-661.
  • 2Kim D, Wang L, Beeoni M, et al. (2R)-4-oxo-4-[3-(triflu- oromethyl)-5, 6-dihydro [1, 2, 4 ] triazolo [4, 3-a ] pyrazin-7 (8H)-yl]-l-(2,4, 5-trifluorophenyl) butan-2-arnine: apotent, orally active dipeptidyl peptidase IV inhibitor for the treat- ment of type 2 diabetes[J].J Med Chem ,2005,48(1) : 141- 151.
  • 3Beconi MG, Reed JR, Teffera Y, et al. Disposition of the dipel~tidyl peptidase 4 inhibitor sitagliptin in rats and dogs [J]. Drug Metab Dispos, 2007,35 (4) : 525-532.
  • 4Vincent SH, Reed JR, berqman AJ, et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [ 14C] Sitagliptin in humans[J]. Drug Metab Dispos, 2007,35 (4) : 533-538.
  • 5Langley AK, Suffoletta TJ,Jennings HR. Dipeptidyl pepti- dase IV inhibitors and the incretin system in type 2 diabetes mellitus[J]. Pharmaeotherapy, 2007,27 (8) : 1163-1180.
  • 6Han SJ, Choi SE, Kanq Y, et al. Effect of sitagliptin plus met- formin on β-cell function, islet integrity and islet gene expres- sion in Zucker diabetic fatty rats[J]. Diabetes Res Clin Pract, 2011,92(2) : 213-222.
  • 7Ferreira L, Teixeira-de-Lemos E, Pinto F, et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)[J]. Mediators lnflamm,2010,2010(55) : 1-11.
  • 8Asehner P, Kipnes MS, Luneeford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy onglycernie control in patients with type 2 diabetes[J]. Diabetes Care, 2006,29 (12) : 2632-2637.
  • 9Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongo- ing metformin therapy in patients with type 2 diabetes inade- quately controlled with metformin alone[J]. Diabetes Care, 2006,29(12) :2638-2643.
  • 10Nauck MA,Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabe- tes inadequately controlled on metforminal one: a random- ized, double-blind noninferioritytrial [J ]. Diabetes Obes Metab,2007,9(2):194-205.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部